MX2023009568A - Materiales y métodos para el direccionamiento mejorado de enlazador. - Google Patents

Materiales y métodos para el direccionamiento mejorado de enlazador.

Info

Publication number
MX2023009568A
MX2023009568A MX2023009568A MX2023009568A MX2023009568A MX 2023009568 A MX2023009568 A MX 2023009568A MX 2023009568 A MX2023009568 A MX 2023009568A MX 2023009568 A MX2023009568 A MX 2023009568A MX 2023009568 A MX2023009568 A MX 2023009568A
Authority
MX
Mexico
Prior art keywords
methods
materials
targeting
enhanced linker
enhanced
Prior art date
Application number
MX2023009568A
Other languages
English (en)
Inventor
Sanjaya Singh
Rajkumar Ganesan
Jun Chen
Iqbal S Grewal
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023009568A publication Critical patent/MX2023009568A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Las moléculas, que incluyen anticuerpos y fragmentos de unión al antígeno de estas que se unen específicamente a un péptido enlazador, y métodos para producir y usar los anticuerpos y fragmentos de unión al antígeno descritos se presentan en la presente descripción; también se presentan en la presente descripción métodos para generar anticuerpos que se unen específicamente a un epítopo inmunorrecesivo.
MX2023009568A 2021-02-16 2022-02-15 Materiales y métodos para el direccionamiento mejorado de enlazador. MX2023009568A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163149883P 2021-02-16 2021-02-16
US202163149865P 2021-02-16 2021-02-16
US202163149892P 2021-02-16 2021-02-16
US202163149857P 2021-02-16 2021-02-16
US202163149872P 2021-02-16 2021-02-16
PCT/US2022/016454 WO2022177902A1 (en) 2021-02-16 2022-02-15 Materials and methods for enhanced linker targeting

Publications (1)

Publication Number Publication Date
MX2023009568A true MX2023009568A (es) 2023-10-24

Family

ID=80819664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009568A MX2023009568A (es) 2021-02-16 2022-02-15 Materiales y métodos para el direccionamiento mejorado de enlazador.

Country Status (11)

Country Link
US (2) US11639396B2 (es)
EP (1) EP4294430A1 (es)
JP (1) JP2024506694A (es)
KR (1) KR20230145423A (es)
AU (1) AU2022224508A1 (es)
BR (1) BR112023016360A2 (es)
CA (1) CA3211114A1 (es)
MX (1) MX2023009568A (es)
TW (1) TW202246356A (es)
UY (1) UY39633A (es)
WO (1) WO2022177902A1 (es)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JPH09506262A (ja) * 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US20020197266A1 (en) 2000-02-08 2002-12-26 Waldemar Debinski Immunotherapy using interleukin 13 receptor subunit alpha 2
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
JP2008511337A (ja) 2004-09-02 2008-04-17 ジェネンテック・インコーポレーテッド ヘテロ多量体分子
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
JP5525729B2 (ja) 2005-11-28 2014-06-18 ゲンマブ エー／エス 組換え一価抗体およびその作製方法
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
KR101781907B1 (ko) 2008-10-31 2017-09-26 얀센 바이오테크 인코포레이티드 파이브로넥틴 타입 ⅲ 도메인 기반 스캐폴드 조성물, 방법 및 용도
EP2396011B1 (en) 2009-02-12 2016-04-13 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
KR101930964B1 (ko) 2010-04-20 2018-12-19 젠맵 에이/에스 이종이량체 항체 ｆｃ-함유 단백질 및 그의 생산 방법
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
BR112013011811A2 (pt) 2010-11-05 2023-02-23 Zymeworks Inc Modelo de anticorpo heterodimérico estável com mutações no domínio fc
RS62689B1 (sr) 2011-11-04 2021-12-31 Zymeworks Inc Dizajn stabilnog heterodimernog antitela sa mutacijama u fc domenu
EP4004055A1 (en) * 2019-07-26 2022-06-01 Janssen Biotech, Inc. Anti-hk2 chimeric antigen receptor (car)

Also Published As

Publication number Publication date
US11639396B2 (en) 2023-05-02
KR20230145423A (ko) 2023-10-17
BR112023016360A2 (pt) 2024-01-23
CA3211114A1 (en) 2022-08-25
US20230374156A1 (en) 2023-11-23
JP2024506694A (ja) 2024-02-14
TW202246356A (zh) 2022-12-01
UY39633A (es) 2022-08-31
EP4294430A1 (en) 2023-12-27
AU2022224508A1 (en) 2023-10-05
WO2022177902A1 (en) 2022-08-25
US20220267472A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
CR20210326A (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
MX2021003580A (es) Nuevas inmunocitocinas para el tratamiento contra el cancer.
MX2021010441A (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
PH12021550662A1 (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2019009119A (es) Conjugados de farmacos y anticuerpos anti-ccr7.
MX2020010227A (es) Construcciones dirigidas a cd22 y usos de las mismas.
CR20220627A (es) Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2019000271A (es) Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.
WO2021207242A3 (en) Anti-mesothelin antigen-binding molecules and uses thereof
MX2021011750A (es) Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos.
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
MX2021006389A (es) Anticuerpo cd3 y uso farmaceutico del mismo.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
PE20230464A1 (es) Union de anticuerpos multiespecificos a bcma
ZA202008095B (en) Humanized antibodies against psma
MX2023014458A (es) Anticuerpos anti-ccr8 y usos de los mismos.
MX2023009568A (es) Materiales y métodos para el direccionamiento mejorado de enlazador.
MX2022014420A (es) Potentes anticuerpos neutralizantes contra el sars-cov-2, generacion y usos de los mismos.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2023000547A (es) Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas.
MX2023007583A (es) Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen.